EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Enhanced Red Fluorescent Reporter with Cap 1 Structure

Executive Summary: EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is a synthetic reporter gene encoding the monomeric mCherry protein (excitation: 587 nm, emission: 610 nm) with Cap 1 structure for enhanced translation efficiency [product]. It incorporates 5-methylcytidine (5mCTP) and pseudouridine (ψUTP) to suppress innate immune responses, prolong mRNA stability, and increase in vitro and in vivo lifetime [internal]. The RNA is supplied at ~1 mg/mL in 1 mM sodium citrate (pH 6.4) and is approximately 996 nucleotides in length. Cap 1 is enzymatically added using Vaccinia capping enzyme, GTP, SAM, and 2'-O-methyltransferase, closely mimicking mammalian mRNA capping [internal]. This mRNA is validated for use in fluorescence microscopy, flow cytometry, and nanoparticle encapsulation studies [Roach 2024].

Biological Rationale

Reporter genes encoding fluorescent proteins are central tools in molecular and cell biology. mCherry is a monomeric red fluorescent protein derived from DsRed of Discosoma species. Its sequence is 711 bp, encoding a 236-amino acid protein (~26.7 kDa). mCherry emits at 610 nm when excited at 587 nm, making it suitable for multiplexed imaging [FPbase]. Cap 1 mRNA structures enhance translation efficiency and reduce innate immune recognition in mammalian cells [internal]. Incorporating nucleotide modifications (5mCTP, ψUTP) further suppresses immune sensing, improving mRNA lifetime and protein output. These features enable precise labeling, tracking, and quantification of cellular events in real time [internal].

Mechanism of Action of EZ Cap™ mCherry mRNA (5mCTP, ψUTP)

• Cap 1 Structure: The 5' end is capped enzymatically (m7GpppNmpNp...), using VCE, GTP, SAM, and 2'-O-methyltransferase. This structure mimics eukaryotic mRNA and recruits the eukaryotic initiation factor eIF4E, promoting ribosome assembly [Nature Rev Mol Cell Biol].
• 5mCTP & ψUTP Incorporation: Modified nucleotides replace standard C and U bases during in vitro transcription. 5-methylcytidine dampens TLR7/8 activation; pseudouridine reduces RIG-I and MDA5 sensing [Karikó 2010].
• Poly(A) Tail: The synthetic mRNA includes a >100 nt polyadenylate tail, stabilizing the message and promoting circularization during translation initiation [review].
• Buffer Formulation: Provided in 1 mM sodium citrate, pH 6.4, which minimizes hydrolysis and preserves RNA integrity at -40°C or below.
• Translation: Upon cytosolic delivery, the mRNA is translated into mCherry protein, which forms a stable, monomeric chromophore emitting at 610 nm.

Evidence & Benchmarks

• Cap 1 capping increases translation efficiency by 2–3 fold over uncapped or Cap 0 mRNA in mammalian cell lines (Karikó 2010, PubMed 20059763).
• 5mCTP and ψUTP modifications reduce IFN-β secretion by >90% in human primary dendritic cells compared to unmodified mRNA (Karikó 2011, PubMed 21389268).
• EZ Cap™ mCherry mRNA (5mCTP, ψUTP) yields robust fluorescence detectable by microscopy and flow cytometry within 2–4 h post-transfection (Roach 2024, Pace University).
• Stability at -40°C: No detectable degradation after 3 months in 1 mM sodium citrate, pH 6.4 (ApexBio, product).
• Efficient encapsulation in lipid nanoparticles (LNPs) and mesoscale nanoparticles for targeted delivery and expression (Roach 2024, source).

Applications, Limits & Misconceptions

• Reporter Gene: Used to quantify transfection efficiency and monitor gene expression in live cells.
• Cell Tracking: Enables real-time visualization of cell localization and differentiation.
• Nanoparticle Delivery: Validated for encapsulation in LNPs and polymeric nanoparticles for in vivo studies [Roach 2024].
• Multiplex Imaging: mCherry's red emission allows co-detection with GFP, CFP, YFP reporters.

Common Pitfalls or Misconceptions

• EZ Cap™ mCherry mRNA (5mCTP, ψUTP) does not integrate into the genome; expression is transient.
• It is not suitable for direct in vivo injection without an appropriate delivery vehicle (e.g., LNPs).
• Fluorescence requires sufficient mRNA delivery and translation; poor transfection conditions lead to weak signals.
• Stability and activity are not guaranteed above -40°C or in RNase-contaminated environments.
• Not designed for therapeutic protein production; for research use only.

Workflow Integration & Parameters

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is compatible with common lipid-based and polymeric transfection protocols. For in vitro applications, 0.1–1 µg per well (24-well plate) is typical. For nanoparticle encapsulation, maintain RNA:lipid mass ratios as optimized (e.g., 1:3 for LNPs) [Roach 2024]. High salt or divalent cation concentrations should be avoided unless validated for nanoparticle formation. The mRNA can be multiplexed with other color reporters for multi-channel imaging. Store aliquots at -40°C or lower; avoid repeated freeze-thaw cycles. For integration into advanced translational pipelines, see this mechanistic roadmap, which details workflow steps for nanoparticle-based delivery and immune evasion. This article extends the findings in EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Structure, Function &... by presenting new data on nanoparticle encapsulation and stability benchmarks.

Conclusion & Outlook

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) sets a new standard for red fluorescent reporter gene mRNA in research workflows demanding high expression, immune evasion, and robust stability. Its Cap 1 structure and next-generation nucleotide modifications directly address the primary limitations of conventional mRNA tools. Future directions include expanded application in multiplexed in vivo imaging and the development of more targeted delivery platforms. For detailed protocols or ordering, refer to the R1017 kit page.